Cancer Research, Statistics, and Treatment

REVIEW ARTICLE - BIOMARKER SERIES
Year
: 2022  |  Volume : 5  |  Issue : 1  |  Page : 97--104

A narrative review of ERBB2 in non-small cell lung carcinoma


Mansi Sharma1, Abhinav Dewan1, Himanshi Diwan2, Shrinidhi Nathany2, Ullas Batra1 
1 Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
2 Department of Pathology (Molecular Diagnostics), Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India

Correspondence Address:
Ullas Batra
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, Sector 5, Rohini, Sir Chhotu Ram Marg, New Delhi - 110 085
India

The plethora of biomarkers and the availability of targeted treatment have revolutionized the therapeutic profile of non-small cell lung cancer (NSCLC). Erythroblastic oncogene B (ERBB2) has been reported in 1%–4% cases of lung adenocarcinoma and recognized as a prognostic marker in a myriad of cancers like pancreatic, gastric, and breast carcinomas. It is more commonly recognized as human epidermal growth factor receptor 2 (HER2). Molecular characterization of NSCLC based on the mechanism of HER2 activation, including mutation, amplification, and overexpression, has recently been widely adopted owing to the differences in prognosis and predictive outcomes. This narrative review of ERBB2 is intended to describe the molecular biology, historical perspective, clinical profile, and therapeutic options for HER2-activated NSCLC. For the purpose of this review, we performed a comprehensive and detailed search in PubMed, Scopus, and My Cancer Genome databases using the keywords “HER2/neu,” “HER2,” “NSCLC,” “pertuzumab,” “trastuzumab,” and “T-DM1.” A total of 59 articles were included in the review.


How to cite this article:
Sharma M, Dewan A, Diwan H, Nathany S, Batra U. A narrative review of ERBB2 in non-small cell lung carcinoma.Cancer Res Stat Treat 2022;5:97-104


How to cite this URL:
Sharma M, Dewan A, Diwan H, Nathany S, Batra U. A narrative review of ERBB2 in non-small cell lung carcinoma. Cancer Res Stat Treat [serial online] 2022 [cited 2022 Jun 25 ];5:97-104
Available from: https://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=1;spage=97;epage=104;aulast=Sharma;type=0